FDA approves first gene therapy for high-risk early bladder cancer
European Pharmaceutical Review
DECEMBER 19, 2022
The failure to achieve a complete response (CR), or the disappearance of all signs of cancer as seen on cystoscopy, biopsied tissue, and urine, is associated with an increased risk of death or a disease-worsening event. Without treatment, the cancer can invade, damage tissues and organs, and spread through the body.
Let's personalize your content